Login
$SMMT
$11.90 +$0.08 (0.68%) After hours

$SMMT SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Duggan Robert W, Director

Received 500,000 shares by exercise or conversion ($530K)

16 Nov 2026 Form 4: Zanganeh Mahkam, Director

Received 500,000 shares by exercise or conversion ($530K)

16 Nov 2026 Form 4: Soni Manmeet Singh, Director

Received 100,000 shares by exercise or conversion ($137K)

16 Nov 2026 8-K: Other Events

Date of Report (Date of Earliest Event Reported): November 15, 2026

04 Nov 2026 8-K: Other Events

We have acted as counsel to Summit Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (File No. 333- 296642) (the “Registration Statement”) filed by the Company with the S...

04 Nov 2026 424B7
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network...

19 Oct 2026 DEF 14A
14 Oct 2026 Form 4: Anand Bhaskar, Chief Accounting Officer

Received 100,000 shares as a grant or award

06 Oct 2026 PRE 14A
29 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”), and AstraZeneca Holdings B.V., a Dutch private limited liability co...

15 Sep 2026 8-K: Other Events

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consist...

14 Sep 2026 8-K: Other Events

1 Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China Ivonescimab Reduced t...

03 Sep 2026 8-K: Other Events

1 Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Summit is Conducting HARMONi-...

26 Aug 2026 8-K: Other Events

1 Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China HARMO...

05 Aug 2026 8-K: Other Events

1 Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer...

23 Jul 2026 8-K: Entry into a Material Definitive Agreement

Summit Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC, as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (“you” or the “Agent”), with...

23 Jul 2026 424B5
23 Jul 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support